Ultragenyx Pharmaceutical(RARE.US) Director Sells US$23,932.32 in Common Stock

$Ultragenyx Pharmaceutical(RARE.US)$ Director Sanders Corazon (Corsee) D. sold 584 shares of common stock on Jul 2, 2024 at an average price of $40.98 for a total value of $23,932.32.Source: Announcem

Futu NewsJul 4 02:49

'Biogen Is Pursuing More Dealmaking This Year, With Plans To Spend Up To $8B' - Endpoint News

'Biogen Is Pursuing More Dealmaking This Year, With Plans To Spend Up To $8B' - Endpoint News

BenzingaJun 27 23:39

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare

GlobeNewswireJun 21 04:30

Piper Sandler Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $135

Piper Sandler analyst Christopher Raymond maintains $Ultragenyx Pharmaceutical(RARE.US)$ with a buy rating, and maintains the target price at $135.According to TipRanks data, the analyst has a success

Futu NewsJun 20 20:31 · Ratings

TD Cowen Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $61

TD Cowen analyst Yaron Werber maintains $Ultragenyx Pharmaceutical(RARE.US)$ with a buy rating, and maintains the target price at $61.According to TipRanks data, the analyst has a success rate of 54.0

Futu NewsJun 17 18:31 · Ratings

Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Shares of AMMO, Inc. (NASDAQ:POWW) fell sharply during Friday's session following fourth-quarter results.AMMO reported a fourth-quarter profit of 1 cent per share, compared to market expectations for

BenzingaJun 15 02:13